175 related articles for article (PubMed ID: 29724589)
1. Discovery of evocalcet, a next-generation calcium-sensing receptor agonist for the treatment of hyperparathyroidism.
Miyazaki H; Ikeda Y; Sakurai O; Miyake T; Tsubota R; Okabe J; Kuroda M; Hisada Y; Yanagida T; Yoneda H; Tsukumo Y; Tokunaga S; Kawata T; Ohashi R; Fukuda H; Kojima K; Kannami A; Kifuji T; Sato N; Idei A; Iguchi T; Sakairi T; Moritani Y
Bioorg Med Chem Lett; 2018 Jun; 28(11):2055-2060. PubMed ID: 29724589
[TBL] [Abstract][Full Text] [Related]
2. A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro.
Kawata T; Tokunaga S; Murai M; Masuda N; Haruyama W; Shoukei Y; Hisada Y; Yanagida T; Miyazaki H; Wada M; Akizawa T; Fukagawa M
PLoS One; 2018; 13(4):e0195316. PubMed ID: 29614098
[TBL] [Abstract][Full Text] [Related]
3. [Pharmacological and clinical profiles of a novel calcimimetic, evocalcet (ORKEDIA
Tokunaga S; Endo Y; Kawata T
Nihon Yakurigaku Zasshi; 2019; 154(1):35-43. PubMed ID: 31308348
[TBL] [Abstract][Full Text] [Related]
4. Development of AC265347-Inspired Calcium-Sensing Receptor Ago-Positive Allosteric Modulators.
Dinh LV; DeBono A; Keller AN; Josephs TM; Gregory KJ; Leach K; Capuano B
ChemMedChem; 2021 Nov; 16(22):3451-3462. PubMed ID: 34216111
[TBL] [Abstract][Full Text] [Related]
5. Calcimimetics and hyperparathyroidism.
Krebs LJ
Curr Opin Investig Drugs; 2004 Oct; 5(10):1080-5. PubMed ID: 15535429
[TBL] [Abstract][Full Text] [Related]
6. International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.
Leach K; Hannan FM; Josephs TM; Keller AN; Møller TC; Ward DT; Kallay E; Mason RS; Thakker RV; Riccardi D; Conigrave AD; Bräuner-Osborne H
Pharmacol Rev; 2020 Jul; 72(3):558-604. PubMed ID: 32467152
[TBL] [Abstract][Full Text] [Related]
7. Personalised medicines for familial hypercalcemia and hyperparathyroidism.
Josephs TM; Zhang F; Dinh LV; Keller AN; Conigrave AD; Capuano B; Gregory KJ; Leach K
J Mol Endocrinol; 2022 May; 69(1):243-257. PubMed ID: 35318962
[TBL] [Abstract][Full Text] [Related]
8. Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet.
Reh CM; Hendy GN; Cole DE; Jeandron DD
J Clin Endocrinol Metab; 2011 Apr; 96(4):E707-12. PubMed ID: 21289269
[TBL] [Abstract][Full Text] [Related]
9. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism.
Akizawa T; Ikejiri K; Kondo Y; Endo Y; Fukagawa M
Ther Apher Dial; 2020 Jun; 24(3):248-257. PubMed ID: 31486206
[TBL] [Abstract][Full Text] [Related]
10. Effects of evocalcet on parathyroid calcium-sensing receptor and vitamin D receptor expression in uremic rats.
Saito T; Mizobuchi M; Sakai M; Kawata T; Kitayama T; Kato T; Suzuki T; Ogata H; Koiwa F; Honda H
FASEB J; 2023 Aug; 37(8):e23094. PubMed ID: 37462513
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients.
Walter S; Baruch A; Dong J; Tomlinson JE; Alexander ST; Janes J; Hunter T; Yin Q; Maclean D; Bell G; Mendel DB; Johnson RM; Karim F
J Pharmacol Exp Ther; 2013 Aug; 346(2):229-40. PubMed ID: 23674604
[TBL] [Abstract][Full Text] [Related]
12. Extracellular calcium-sensing receptors in the parathyroid gland, kidney, and other tissues.
Quarles LD
Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):349-55. PubMed ID: 12815330
[TBL] [Abstract][Full Text] [Related]
13. [Calcimimetics].
Messa P; Como G; Brezzi B
G Ital Nefrol; 2006; 23(1):12-21. PubMed ID: 16521071
[TBL] [Abstract][Full Text] [Related]
14. Cinacalcet: pharmacological and clinical aspects.
Messa P; Alfieri C; Brezzi B
Expert Opin Drug Metab Toxicol; 2008 Dec; 4(12):1551-60. PubMed ID: 19040330
[TBL] [Abstract][Full Text] [Related]
15. Sensing Extracellular Calcium - An Insight into the Structure and Function of the Calcium-Sensing Receptor (CaSR).
Chavez-Abiega S; Mos I; Centeno PP; Elajnaf T; Schlattl W; Ward DT; Goedhart J; Kallay E
Adv Exp Med Biol; 2020; 1131():1031-1063. PubMed ID: 31646544
[TBL] [Abstract][Full Text] [Related]
16. Novel strategies in drug discovery of the calcium-sensing receptor based on biased signaling.
Thomsen AR; Smajilovic S; Bräuner-Osborne H
Curr Drug Targets; 2012 Sep; 13(10):1324-35. PubMed ID: 22702634
[TBL] [Abstract][Full Text] [Related]
17. GENETICS IN ENDOCRINOLOGY: Gain and loss of function mutations of the calcium-sensing receptor and associated proteins: current treatment concepts.
Mayr B; Schnabel D; Dörr HG; Schöfl C
Eur J Endocrinol; 2016 May; 174(5):R189-208. PubMed ID: 26646938
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic use of calcimimetics.
Hebert SC
Annu Rev Med; 2006; 57():349-64. PubMed ID: 16409154
[TBL] [Abstract][Full Text] [Related]
19. Novel homozygous inactivating mutation of the calcium-sensing receptor gene (CASR) in neonatal severe hyperparathyroidism-lack of effect of cinacalcet.
Atay Z; Bereket A; Haliloglu B; Abali S; Ozdogan T; Altuncu E; Canaff L; Vilaça T; Wong BY; Cole DE; Hendy GN; Turan S
Bone; 2014 Jul; 64():102-7. PubMed ID: 24735972
[TBL] [Abstract][Full Text] [Related]
20. [Clinical application of calcimimetics].
Nishi H; Fukagawa M
Clin Calcium; 2004 May; 14(5):756-9. PubMed ID: 15577038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
